A single 17D yellow fever vaccination provides lifelong immunity; characterization of yellow-fever-specific neutralizing antibody and T-cell responses after vaccination

PLoS ONE

Volumn 11, Issue 3, 2016, Pages

  Wieten, Rosanne W ^a   Jonker, Emile F F ^c   Van Leeuwen, Ester M M ^a   Remmerswaal, Ester B M ^a   Ten Berge, Ineke J M ^a   De Visser, Adriëtte W ^c   Van Genderen, Perry J J ^d   Goorhuis, Abraham ^a   Visser, Leo G ^c   Grobusch, Martin P ^a   De Bree, Godelieve J ^a,b  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b AMSTERDAM INSTITUTE FOR GLOBAL HEALTH AND DEVELOPMENT   (Netherlands)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d Havenziekenhuis   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CD27 ANTIGEN; CD45RA ANTIGEN; EOMESODERMIN; NEUTRALIZING ANTIBODY; TETRAMER; TRANSCRIPTION FACTOR T BET; VIRUS ANTIBODY; YELLOW FEVER VACCINE;

ADULT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BLOOD SAMPLING; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; EFFECTOR CELL; FEMALE; HUMAN; HUMAN CELL; IMMUNOLOGICAL MEMORY; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PRACTICE GUIDELINE; PROTEIN EXPRESSION; SCHOOL CHILD; VACCINATION; VIRUS NEUTRALIZATION; YELLOW FEVER; YELLOW FEVER VIRUS; CELL PROLIFERATION; IMMUNOLOGY; PROSPECTIVE STUDY; SERODIAGNOSIS; VIRAL PLAQUE ASSAY;

ANTIBODIES, NEUTRALIZING; CD8-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; HUMANS; NEUTRALIZATION TESTS; PROSPECTIVE STUDIES; VIRAL PLAQUE ASSAY; YELLOW FEVER VACCINE;

EID: 84962278637     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0149871     Document Type: Article

References (63)

1. Monath TP, Cetron MS, Teuwen DE. Yellow fever vaccine. In Plotkin SA, Orenstein WA, Offit PA, eds. Vaccines. 5th ed. Philadelphia: Saunders Elsevier; 2008. pp. 959-1056.
2. Strategic Advisory Group of Experts, Background Paper on Yellow Fever Vaccine. Geneva: WHO, 2013.
3. Gotuzzo E, Yactayo S, Cordova E. Review article: Efficacy and duration of immunity after yellow fever vaccination: systematic review on the need for a booster every 10 years. Am J Trop Med Hyg. 2013; 89: 434-444. doi: 10.4269/ajtmh.13-0264 PMID: 24006295
4. Grobusch MP, Goorhuis A, Wieten RW, Verberk JDM, Jonker EFF, Genderen PJJ, et al. Yellow fever revaccination guidelines change - a decision too feverish? Clin Micr Inf. 2013; 19: 885-886.
5. Patel D, Simons H. Yellow fever vaccination: Is one Dose always Enough? Travel Med Infect Dis, 2013; 11: 266-273. doi: 10.1016/j.tmaid.2013.08.007 PMID: 24074827
6. Bassi MR, Kongsgaard M, Steffensen MA, Fenger C, Rasmussen M, Skjødt K, et al. CD8+T-cells complement antibodies in protecting against yellow fever virus. J Immunol. 2015; 194:1141-1153. doi: 10.4049/jimmunol.1402605 PMID: 25539816
7. Mason RA, Tauraso NM, Spertzel RO, Ginn RK. Yellow fever vaccine: direct challenge of monkeys given graded doses of 17D vaccine. Appl Microbiol. 1973; 25: 539-544. PMID: 4633476
8. Barrett ADT, Teuwen D. Yellow fever vaccine - how does it work and why do rare cases of serious adverse events take place? Curr Opin Immunol. 2009; 21:1-6.
9. Niedrig M, Lademann M, Emmerich P, Lafrenz M. Assessment of IgG antibodies against yellow fever visud after vaccination with 17D by different assays: neutralization test, haemagglutination inhibition test, immunofluorescence assay and ELISA. Trop Med Int Health. 1999; 4: 867-871. PMID: 10632996
10. Poland JD, Calisher CH, Monath TP, Downs WG, Murphy K. Persistence of neutralizing antibody 30-35 years after immunization with 17D yellow fever vaccine. Bull World Health Organ. 1981; 59: 895-900. PMID: 6978196
11. Collaborative group for studies on yellow fever vaccines. Duration of post-vaccination immunity against yellow fever in adults. Vaccine. 2014; 32:4977-4984. doi: 10.1016/j.vaccine.2014.07.021 PMID: 25090646
12. Pulendran B. Learning immunology from the yellow fever vaccine: innate immunity to systems vaccinology. Nat Rev Immunol. 2009; 9: 741-747. doi: 10.1038/nri2629 PMID: 19763148
13. Wrammert J, Miller J, Akondy R, Ahmed R. Human immune memory to yellow fever and smallpox vaccination. J Clin Immunol. 2009; 29:151-157. doi: 10.1007/s10875-008-9267-3 PMID: 19052852
14. Co MD, Terajima M, Cruz J, Ennis FA, Rothman AL. Human cytotoxicT lymphocyte responses to live attenuated 17D yellow fever vaccine: identification of HLA-B35-restricted CTL epitopes on nonstructural proteins NS1, NS2b, NS3, and the structural protein E. Virology. 2002; 293:151-163. PMID: 11853408
15. Akondy RS, Monson ND, Miller JD, Edupuganti S, Teuwen D, Wu H, et al. The yellow fever virus vaccine induces a broad and polyfunctional human memory CD8+T-cell response. J Immunol. 2009; 183: 7919-7930. doi: 10.4049/jimmunol.0803903 PMID: 19933869
16. Blom K, Braun M, Ivarsson MA, Gonzalez VD, Falconer K, Moll M, et al. Temporal dynamics of the primary human T-cell response to yellow fever virus 17Das it matures from an effector to a memory type response. The journal of immunology. 2013; 190: 2150-2158. doi: 10.4049/jimmunol.1202234 PMID: 23338234
17. Appay, van Lier, Sallusto, Roederer. Phenotype and function of human T lymphocyte subsets: consensus and issues. Cytometry Part A. 2008; 73: 975-983.
18. Appay V, Dunbar PR, Callan M, Klenerman P, Gillespie GM, Papagno L, et al. Memory CD8+T-cells vary in differentiation phenotype in different persistent virus infections. Nat Med. 2002; 8: 379-385. PMID: 11927944
19. Sallusto F, Geginat J, Lanzavecchia A. Central memory and effector memory T-cell subsets: function, generation, and maintenance. Annu Rev Immunol. 2004; 22: 745-763. PMID: 15032595
20. Hamann D, Baars PA, Rep MH, Hooibrink B, Kerkhof-Garde SR, Klein MR, et al. Phenotypic and functional separation of memory and effector human CD8+T-cells. J Exp Med. 1997; 186:1407-1418. PMID: 9348298
21. Romero P, Zippelius A, Kurth I, Pittet MJ, Touvrey C, Iancu EM, et al 2007. Four functionally distinct populations of human effector-memory CD8+T lymphocytes. Journal of Immunology, 2007; 178: 4112-4119.
22. van Aalderen MC, Remmerswaal EB, ten Berge IJ, van Lier RA. Blood and beyond: properties of circulating and tissue-resident human virus-specific αβ CD8(+)T-cells. EurJ Immunol. 2014; 44: 934-944. doi: 10.1002/eji.201344269 PMID: 24448915
23. Appay V, Papagno L, Spina CA, Hansasuta P, King A, Jones L, et al. Dynamics of T-cell responses in HIV infection. J. Immunol, 2002; 168:3660-3666. PMID: 11907132
24. Gamadia LE, Remmerswaal EBM, Weel JF, Bemelman F, van Lier RA, ten Berge IJ. Primary immune responses to human CMV: a critical role for IFN-gamma-producingCD4+T-cells in protection against CMV disease. Blood. 2003; 101: 2686-2692. PMID: 12411292
25. Badr G, Bedard N, Abdel-Hakeem MS, Trautmann L, Willems B, Villeneuve JP, et al. Early interferon therapy for hepatitis C virus infection rescues polyfunctional, long-lived CD8+ memory T-cells. J. Virol. 2008; 82:10017-10031. doi: 10.1128/JVI.01083-08 PMID: 18667516
26. Blom K, Braun M, Pakalniene J, Dailidyte L, Béziat V, Lampen MH, et al. Specificity and dynamics of effector and memory CD8 T-cell responses in human tick-borne encephalitis virus infection. PLoS Pathog, 2015 Nov 22. 11(1):e1004622. doi: 10.1371/journal.ppat.1004622 PMID: 25611738
27. Nabeshima S, Murata M, Kikuchi K, Ikematsu H, Kashiwagi S, Hayashi J. A reduction in the number of peripheral CD28+CD8+T-cells in the acute phase of influenza. Clin Exp Immunol. 2002; 128: 339-346. PMID: 11985525
28. de Bree GJ, van Leeuwen EM, Out TA, Jansen HM, Jonkers RE, van Lier RA. Selective accumulation of differentiated CD8+ T-cells specific for respiratory viruses in the human lung. J Exp Med. 2005; 202: 1433-1442. PMID: 16301748
29. Knox JJ, Cosma GL, Betts MR, McLane LM. Characterization of T-bet and eomes in peripheral human immune cells. Front Immunol. 2014; 5: 217. doi: 10.3389/fimmu.2014.00217 PMID: 24860576
30. Joshi NS, Cui W, Chandele A, Lee HK, Urso DR, Hagman J, et al. Inflammation directs memory precursor and short-lived effector CD8(+) T-cell fates via the graded expression of T-bet transcription factor. Immunity, 2007; 27: 281-295. PMID: 17723218
31. Banerjee A, Gordon SM, Intlekofer AM, Paley MA, Mooney EC, Lindsten T, et al. Cutting edge: The transcription factor eomesodermin enables CD8+ T-cells to compete for the memory cell niche. J Immunol. 2010; 185: 4988-4992. doi: 10.4049/jimmunol.1002042 PMID: 20935204
32. Kaech SM, Cui W, Transcriptional control of effector and memory CD8+ T-cell differentiation. Nat Rev Immunol. 2012; 12: 749-761. doi: 10.1038/nri3307 PMID: 23080391
33. Intlekofer AM, Takemoto N, Wherry EJ, Longworth SA, Northrup JT, Palanivel VR, et al, Effector and memory CD8+T-cell fate coupled by T-bet and eomesodermin. Nat Immunol. 2005; 6:1236-1244. PMID: 16273099
34. Popescu I, Pipeling MR, Shah PD, Orens JB, McDyer JF. T-bet: Eomes balance, effector function, and proliferation of cytomegalovirus-specific CD8+ T-cells during primary infection differentiates the capacity for durable immune control. J Immunol. 2014; 193: 5709-5722. doi: 10.4049/jimmunol.1401436 PMID: 25339676
35. Hersperger AR, Martin JN, Shin LY, Sheth PM, Kovacs CM, Cosma GL, et al. Increased HIV-specific CD8+ T-cell cytotoxic potential in HIV elite controllers is associated with T-bet expression. Blood, 2011; 117: 3799-3808. doi: 10.1182/blood-2010-12-322727 PMID: 21289310
36. Guy B, Nougarede N, Begue S, Sanchez V, Souag N, Carre M, et al. Cell-mediated immunity induced by chimeric tetravalent dengue vaccine in naive or flavivirus-primed subjects. Vaccine, 2008; 26: 5712-5721. doi: 10.1016/j.vaccine.2008.08.019 PMID: 18762226
37. Co MD, Kilpatrick ED, Rothman AL. Dynamics of the CD8 T-cell response following yellow fever virus 17D immunization. Immunology. 2009; 128: e718-727. doi: 10.1111/j.1365-2567.2009.03070.x PMID: 19740333
38. De Madrid AT, Porterfield JS. A simple micro-culture method for the study of group B arbovirusses. B World Health Organ. 1969; 40:113-121.
39. Ewen CL, Kane KP, Bleackley RC. A quarter century of granzymes. Cell Death Differ. 2012; 19: 28-35. doi: 10.1038/cdd.2011.153 PMID: 22052191
40. Hertoghs KM, Moerland PD, van Stijn A, Remmerswaal EBM, Yong SL, van de Berg PJ, et al. Molecular profiling of cytomegalovirus-induced human CD8+T-cell differentiation. J Clin Invest. 2010; 120: 4077-4090. doi: 10.1172/JCI42758 PMID: 20921622
41. Bratke K, Kuepper M, Bade B, Virchow JC Jr, Luttmann W, Differential expression of human granzymes A, Band Kin natural killer cells and during CD8+T-cell differentiation in peripheral blood. Eur J Immunol. 2005; 35: 2608-2616. PMID: 16106370
42. Haining WN, Wherry EJ. Integrating genomic signatures for immunologic discovery. Immunity. 2010; 32:152-161. doi: 10.1016/j.immuni.2010.02.001 PMID: 20189480
43. Doering TA, Crawford A, Angelosanto JM, Paley MA, Ziegler CG, Wherry EJ. Network analysis reveals centrally connected genes and pathways involved in CD8+ T-cell exhaustion versus memory. Immunity. 2012; 37:1130-1144. doi: 10.1016/j.immuni.2012.08.021 PMID: 23159438
44. Paley MA, Kroy DC, Odorizzi PM, Johnnidis JB, Dolfi DV, Barnett BE, et al. Progenitor and terminal subsets of CD8+T-cells cooperate to contain chronic viral infection. Science, 2012; 338:1220-1225. doi: 10.1126/science.1229620 PMID: 23197535
45. Kao C, Oestreich KJ, Paley MA, Crawford A, Angelosanto JM, Ali MA, et al. Transcription factor T-bet represses expression of the inhibitory receptor PD-1 and sustains virus-specific CD8+ T-cell responses during chronic infection. Nat Immunol. 2011; 12: 663-671. doi: 10.1038/ni.2046 PMID: 21623380
46. Lazarevic V, Glimcher LH, Lord GM. T-bet: a bridge between innate and adaptive immunity. Nat Rev Immunol. 2013; 13: 777-789. doi: 10.1038/nri3536 PMID: 24113868
47. Dolfi DV, Mansfield KD, Polley AM, Doyle SA, Freeman GJ, Pircher H, et al. Increased T-bet is associated with senescence of influenza virus-specific CD8T-cells in aged humans. J Leukoc Biol. 2013; 93: 825-836. doi: 10.1189/jlb.0912438 PMID: 23440501
48. Fuertes Marraco SA, Soneson C, Cagnon L, Gannon PO, Allard M, Abed Maillard S, et al. Long-lasting stem cell-like memory CD8+T-cells with a naive-like profile upon yellow fever vaccination. Sci Transl Med. 2015; 7: 282ra48. doi: 10.1126/scitranslmed.aaa3700 PMID: 25855494
49. Sallusto F, Lenig D, Förster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature. 1999; 401: 708-712. PMID: 10537110
50. Wirth TC, Harty JT, Badovinac VP. Modulating numbers and phenotype of CD8+ T-cells in secondary immune responses. Eur J Immunol. 2010; 40:1916-1926. doi: 10.1002/eji.201040310 PMID: 20411564
51. Ahmed R, Akondy RS. Insights into human CD8(+) T-cell memory using the yellow fever and smallpox vaccines. Immunol Cell Biol. 2011; 89: 340-345. doi: 10.1038/icb.2010.155 PMID: 21301482
52. He XS, Mahmood K, Maecker HT, Holmes TH, Kemble GW, Arvin AM, et al. Analysis of the frequencies and of the memory T cell phenotypes of human CD8+ T cells specific for influenza A viruses J Inf Dis. 2003; 187:1075-1084.
53. Hoji A, Rinaldo CR Jr. Human CD8+Tcells specific for influenza A virus M1 display broad expression of maturation-associated phenotypic markers and chemokine receptors. Immunology. 2005; 115: 239-245. PMID: 15885130
54. de Bree GJ, Heidema J, van Leeuwen EM, van Bleek GM, Jonkers RE, Jansen HM, van Lier RA, Out TA. 2005. Respiratory syncytial virus-specific CD8+memory T cell responses in elderly persons. J Inf Dis. 2005; 191:1710-1718.
55. Wieten RW, Goorhuis A, Jonker EFF, de Bree GJ, de Visser AW, van Genderen PJJ, et al. 17D yellow fever vaccine elicits comparable long-term immune responses in healthy individuals and immunocompromised patients. manuscript submitted
56. van Aalderen MC, Remmerswaal EB, Verstegen NJ, Hombrink P, ten Brinke A, Pircher H, et al. Infection history determines the differentiation state of human CD8+T-cells. J Virol. 2015; 89: 5110-5123. doi: 10.1128/JVI.03478-14 PMID: 25717102
57. Lau LL, Jamieson BD, Somasundaram T, Ahmed R. Cytotoxic T-cell memory without antigen. Nature. 1994; 369: 648-652 PMID: 7516038
58. Murali-Krishna K, Lau LL, Sambhara S, Lemonnier F, Altman J, Ahmed R. Persistence of memory CD8 T-cells in MHC class I-deficient mice. Science. 286:1377-1381 PMID: 10558996
59. Reinhardt B, Jaspert R, Niedrig M, Kostner C, L'Age-Stehr J. Development of viremia and humoral and cellular parameters of immune activation after vaccination with yellow fever virus strain 17D: a model of human flavivirus infection. J Med Virol. 1998; 56:159-167. PMID: 9746073
60. Wherry EJ, Puorro KA, Porgador A, Eisenlohr LC. The induction of virus-specific CTL as a function of increasing epitope expression: responses rise steadily until excessively high levels of epitope are attained. J Immunol. 1999; 163:3735-3745. PMID: 10490969
61. Plotkin SL, Plotkin SA, General aspects of vaccination, Section 1, Chapter 2, pp. 17-36. In Plotkin SA, Orenstein WA, Offit PA, eds. Vaccines. 6th ed. Philadelphia: Saunders Elsevier; 2008. pp. 17-36.
62. Coulange Bodilis H, Benabdelmoumen G, Gergely A, Goujon C, Pelicot M, Poujol P, et al. Long-term persistence of yellowfever neutralizing antibodies in persons aged 60 years and older. Bull Soc Pathol Exot. 2011; 104: 260-265. doi: 10.1007/s13149-011-0135-7 PMID: 21336654
63. Gómez SY, Ocazionez RE. Yellowfever virus 17D neutralising antibodies in vaccinated Colombian people and unvaccinated ones having immunity against dengue. Rev Salud Publica (Bogota), 2008; 10: 796-807.